Clinical Trial Update: Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) [NA]

View source ↗

Summary

A clinical trial evaluating calprotectin (CALPRO) as a biomarker for COVID-19 severity (NCT04953312) has been withdrawn; the study also involved patients with c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Severe/Moderate Coronavirus, Chronic Myelomonocytic Leukemia | NA | Status: WITHDRAWN